AstraZeneca Granted Approval by FDA for Imfinzi for BTC

AstraZeneca got approval for Imfinzi in combination with gemcitabine and cisplatin for adult patients with locally advanced or metastatic biliary tract cancer, the US FDA said.

• Application was granted priority review and orphan drug designation

NOTE

• AstraZeneca Plc rose 0.4% to GBp10,618.00 as of last close
  • The average 12-month price target of GBp12,015.00 is 13.2% above the current price
  • 29 buys, 7 holds, 0 sells

To view the source of this information, click here

To contact the reporter on this story:
Greg Chang in San Francisco at gchang1@bloomberg.net

To contact the editor responsible for this story:
Chakradhar Adusumilli at cadusumilli@bloomberg.net ...